Welcome: Guest | Site Use Options | Register | Login |

NIH 2020 Rapid Point-Of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients

Rapid Point-Of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients

 Project Summary
Program: SBIR Agency: NIH
(NIAID)
Phase I Year: 2020 Phase II Year: 2021
Phase I Dollars: Phase II Dollars:
Principal Investigator:

   Phase I Abstract   
Epilepsy, a disorder of the brain manifested by seizures, is the fourth most prevalent neurological disease, affecting over 50 million people worldwide, or about 1 out of 150 individuals on average. .....

   Phase II Abstract   
Epilepsy, a disorder of the brain manifested by seizures, is the fourth most prevalent neurological disease, affecting over 50 million people worldwide, or about 1 out of 150 individuals on average. .....

Recipient Firm

1 Grant Street Suite 300
Framingham, MA 01702

(617) 834-0950
info@kepheradx.com
www.kepheradx.com

Principal point of contact
President/CEO:  Andrew E Levin

SBIR firms in the news



Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com